[Geneva – 7 July 2017]
Joint WHO and GARDP/DNDi News Release: Data from 77 countries show that antibiotic resistance is making gonorrhoea – a common sexually-transmitted infection—much harder, and sometimes impossible, to treat.
[Geneva – 7 July 2017]
[Boston, Geneva – 6 July 2017]
First partnering deal for newly-created GARDP with Entasis includes access and stewardship strategy to tackle drug-resistant gonorrhea
Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhea.
[Deutsch] [Français] [Português]
[Khartoum, Sudan – 19 June 2017]
First ever double-blind study for disease so neglected that it only recently was added to WHO list of neglected tropical diseases
The first-ever double-blind, randomized clinical trial for an effective treatment for the severely neglected disease mycetoma has enrolled its first patient at the Mycetoma Research Centre (MRC) in Khartoum, Sudan.
[London and New York – May 3, 2017]
Indian, UK and US students to help discover desperately-needed drug leads for visceral leishmaniasis
The non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) has launched a collaborative project with five universities in India, the UK, and the US to harness the capacity of university teaching laboratories and task students with discovering potential new drugs for patients living with neglected diseases.
[Geneva, Switzerland – April 19, 2017]
The pharmaceutical company Merck has become the sixth company to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, a new initiative to accelerate and cut the cost of early-stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.
[Los Angeles, USA – April 13, 2017]
A study of almost 5,000 Latin American-born residents of Los Angeles County found that 1.24% tested positive for Chagas disease, a parasitic infection that can cause life-threatening heart damage if not treated early. Chagas disease is one of the leading causes of heart failure in Latin America.
[Tokyo, Japan – March 30, 2017]
Daiichi Sankyo announces collaborative research on drugs for neglected diseases
Daiichi Sankyo Company, Limited (hereafter, “Daiichi Sankyo”), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (hereafter, “DNDi”) with regard to a new research program, the Hit-to-Lead Project, with the aim to develop drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
[Seattle, USA – February 14, 2017]
Landmark study proves that “super-boosting” approach counters negative interaction between key HIV and TB drugs
The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.
[Geneva, Switzerland – October 22, 2016]
Potentially refutes assumption that Loa Loa is a benign disease and highlights R&D gap for filarial diseases
A filarial worm infection called Loiasis that affects over 10 million people in Africa and has been assumed to be a relatively harmless disease could possibly contribute to increased risk of death, according to a study recently published in Lancet Infectious Diseases.
[Geneva, Switzerland – September 22, 2016]
The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce financial support from the Swiss Government to the DNDi-WHO joint initiative Global Antibiotic Research and Development Partnership (GARDP) launched earlier this year.
As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing ‘4-in-1’ fixed-dose combinations using the World Health Organization (WHO) recommended treatment regimen for infants and young children. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).
[Summit, New Jersey and Geneva, Switzerland – June 15, 2016]
First US-based biopharmaceutical partner to join global consortium
The biopharmaceutical company Celgene has become the fifth company to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.
[8 June 2016 – Rio de Janeiro, Brazil]
Plans will boost access to Chagas treatment throughout Americas
In a bid to overturn a situation where less than 1% of people with Chagas disease have access to treatment, non-profit drug development organisation Drugs for Neglected Diseases initiative (DNDi), pharmaceutical company Chemo Group and non-profit foundation Mundo Sano are entering into a formal collaboration to boost affordable access to benznidazole, by registering this essential medicine in countries affected by this deadly disease, including the US.
[1 June 2016 – Tokyo, Japan]
Non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) welcomes the G7-related announcement from the Government of Japan to replenish the Global Health Innovative Technology Fund (GHIT Fund) for research and development to combat infectious diseases including neglected tropical diseases.
[28 May 2016 – Geneva, Switzerland]
Move helps bring the disease to the attention of governments and funders
During the 69th World Health Assembly, the decision-making body of the World Health Organization (WHO), the devastating infection mycetoma has been added to WHO’s official list of ‘neglected tropical diseases,’ an important step in addressing the suffering of patients afflicted by this disease around the globe. Mycetoma becomes the 18th disease to be included on this list.
[24 May 2016 – Geneva, Switzerland]
A new joint initiative by the WHO and DNDi that seeks to develop new antibiotic treatments to address the major public health threat of antimicrobial resistance announced today that it has received the necessary seed funding to build its scientific strategy, initial R&D portfolio, and start-up team.
[The International Liver Congress 2016, Barcelona, Spain, 13 April 2016]
Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300
The Drugs for Neglected Diseases initiative (DNDi) and the Egyptian drug manufacturer Pharco Pharmaceuticals have signed agreements covering the clinical testing and scale-up of a hepatitis C treatment regimen at a price of just under $300.
[Español] [Français] [Português]
[Putrajaya, 13 January 2016]
Joint Media Release: Ministry of Health Malaysia and the Drugs for Neglected Diseases initiative (DNDi)
The Drugs for Neglected Diseases initiative (DNDi) and the Ministry of Health of the Government of Malaysia have agreed to work together to develop a public health approach to Hepatitis C within the framework of the future National Strategic Plan on viral hepatitis. The immediate goal is to conduct clinical studies of promising new treatment regimens for Hepatitis C, to be followed by scale-up of treatment for patients, with the overall objective of ensuring equitable access to affordable and effective treatments for patients suffering from this disease in Malaysia.
[New York, December 14, 2015]
As reported this weekend in the New York Times, the pharmaceutical company KaloBios has announced its intention to register the drug benznidazole with the United States Food and Drug Administration (FDA) and to charge exorbitant prices for this treatment, which is an essential medicine for Chagas disease, the leading parasitic killer in Latin America. By registering this drug in the U.S., KaloBios also hopes to obtain a neglected disease “priority review voucher,” which it would likely be able to sell for a large sum – the latest “priority review voucher” was sold for $350 million.
Although details about this move are still emerging, documents filed with the US Securities and Exchange Commission (SEC) show that KaloBios intends to price benznidazole at levels “similar to Hepatitis C antivirals,” which are some of the most highly-priced drugs on the planet. Currently, benznidazole is available in many Latin American countries for $60-100, while the new generation of Hepatitis C antivirals cost up to $94,000.
[Nairobi, Kenya – 1 December 2015]
One small but important step towards better treatment for children
The Drugs for Neglected Diseases initiative (DNDi) has begun an implementation study of a recently-approved paediatric antiretroviral (ARV) treatment in order to address the urgent need for better medicines for children living with HIV. This study, which has begun in Kenya, is an important step towards DNDi’s ultimate goal of developing, together with the Indian generic pharmaceutical company Cipla Ltd and in partnership with UNITAID, improved and easy-to-take combinations of the key HIV medicines children need to survive into adulthood.